Back to Results

Qiagen NV (QGEN)

Qiagen N.V. is a Netherlands-based life sciences tools and services company listed on the NYSE under the ticker QGEN. The company develops sample-to-insight solutions that help convert biological material into molecular information for research, diagnostics, and applied testing. Its portfolio includes consumables and instruments for nucleic acid stabilization, purification, quality control, genotyping, gene expression, viral and bacterial analysis, and related laboratory workflows. Qiagen also supplies immune response products, oncology and reproductive health assays, genomic variant analysis tools, PCR solutions, NGS panels, bioinformatics offerings, and custom laboratory and genomic services. In addition, the company provides software-as-a-service and serves customers in molecular diagnostics, academia, pharmaceuticals, and applied testing. Qiagen was founded in 1984 and is headquartered in Venlo, the Netherlands.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-QGEN
$44.37
9.7% Upside
Fair
$44.07
9.0% Upside
Fair
Great
—
—
0.35
0.9%
August 5, 2026
20.8x
2.5x
4.0x
8.371 B
9.369 B
16.6%
99.3%
11.9
13.5%
102.2%
Valuation • Fair Value

Qiagen NV (NYSE-QGEN) Fair Value by Valuation Model

Compare the primary fair value estimate for Qiagen NV (NYSE-QGEN) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$44.37

Estimated upside of 9.7% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$46.52

Discounted cash flow valuation reference.

Ben Graham Formula Value

$21.58

Classic Ben Graham valuation formula reference.

DDM Fair Value

$48.79

Dividend discount model valuation reference.

EPV Fair Value

$22.92

Earnings power value estimate.

Comps Fair Value

$44.33

Comparable-company valuation reference.

Analyst Price Target

$44.07

Analysts imply upside of 9.0%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Qiagen NV (NYSE-QGEN) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Qiagen NV (NYSE-QGEN)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

2.099 B

Current operating scale indicator.

Revenue Forecast

2.142 B

Forward revenue estimate.

EBITDA

727.7 M

Current operating profitability reference.

EBITDA Forecast

820.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Qiagen NV (NYSE-QGEN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Qiagen NV (NYSE-QGEN)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.50

No elevated caution signal from this screen.

Altman Z-Score

11.9

Relatively strong balance-sheet zone.

FCF / Net Income

102.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Qiagen NV (NYSE-QGEN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Qiagen NV (NYSE-QGEN)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 5, 2026

Days to Earnings

15

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.9%

Income yield reference.

Upcoming Dividend

0.35

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

13.5%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Qiagen NV (NYSE-QGEN), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Qiagen NV (NYSE-QGEN) Stock Forecast & Technical Outlook

Review Qiagen NV (NYSE-QGEN) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Qiagen NV (NYSE-QGEN) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Qiagen NV (NYSE-QGEN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Qiagen NV (NYSE-QGEN) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Neutral

The weekly technical read for Qiagen NV (NYSE-QGEN) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Qiagen NV (NYSE-QGEN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Qiagen NV (NYSE-QGEN)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Qiagen NV (NYSE-QGEN) has a Hold consensus, with 5 buy, 7 hold and 0 sell recommendations in the current data set.

Buy 5
Hold 7
Sell 0
FAQ • Fast Investor Answers

Qiagen NV (NYSE-QGEN) Stock FAQ

Quick answers about Qiagen NV (NYSE-QGEN) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$44.37
Estimated upside 9.7%
Valuation Rating
Undervalued
Estimated upside of 9.7%
Analyst Target
$44.07
Implied upside 9.0%
Financial Health
Great
Current financial-health read

The current fair value estimate for Qiagen NV (NYSE-QGEN) is $44.37. This implies an estimated upside of 9.7% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 9.7% versus the current market price.

The available analyst price target for Qiagen NV (NYSE-QGEN) is $44.07. The analyst target implies estimated upside of 9.0%.

The current financial health read for Qiagen NV (NYSE-QGEN) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Qiagen NV (NYSE-QGEN) is August 5, 2026.

Based on the current data, dividend yield is 0.9%, upcoming dividend amount is 0.35.

The current P/E ratio listed for Qiagen NV (NYSE-QGEN) is 20.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Qiagen NV is 8.371 B.

The current enterprise value listed for Qiagen NV is 9.369 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Qiagen NV is NYSE-QGEN, and the stock is listed on NYSE.

Qiagen NV (NYSE-QGEN) is listed on NYSE.

The current debt-to-total-capital ratio listed for Qiagen NV is 16.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Qiagen NV is 99.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks on NYSE View more

Thermo Fisher Scientific Inc (TMO) Thermo Fisher Scientific Inc (TMO)
Danaher Corporation (DHR) Danaher Corporation (DHR)
Agilent Technologies Inc (A) Agilent Technologies Inc (A)
Waters Corporation (WAT) Waters Corporation (WAT)
IQVIA Holdings Inc (IQV) IQVIA Holdings Inc (IQV)
Mettler-Toledo International Inc (MTD) Mettler-Toledo International Inc (MTD)
West Pharmaceutical Services Inc (WST) West Pharmaceutical Services Inc (WST)
Revvity Inc (RVTY) Revvity Inc (RVTY)
Charles River Laboratories (CRL) Charles River Laboratories (CRL)
Bio-Rad Laboratories B (BIOb) Bio-Rad Laboratories B (BIOb)
Bio-Rad Laboratories Inc (BIO) Bio-Rad Laboratories Inc (BIO)
Avantor Inc (AVTR) Avantor Inc (AVTR)
Stevanato Group SpA (STVN) Stevanato Group SpA (STVN)
Ginkgo Bioworks Holdings (DNA) Ginkgo Bioworks Holdings (DNA)